CAAMTECH, INC.

This disclosure relates to crystalline bis(4-hydroxy-N,N-di-n-propyltryptammonium) fumarate tetrahydrate (4-HO-DPT fumarate·4H 2 O) and to crystalline 4-hydroxy-N,N-di-n-propyl-tryptammonium chloride (4-HO-DPT chloride). Compositions containing crystalline 4-HO-DPT fumarate·4H 2 O or crystalline 4-HO-DPT chloride, and methods of use are disclosed.

The disclosure relates to 5-methoxy-N,N-diallyltryptamine (“5-MeO-DALT”), bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (“5-MeO-DALT fumarate”), and crystalline bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (“5-MeO-DALT fumarate”), compositions containing them, and the methods of treatment using them.

The disclosure relates to compounds of formula (I): Among the substituents in a compound of formula (I), one of R 4 and R 5 is hydrogen and the other of R 4 and R 5 is 13 OSO 2 R 6 . The disclosure relates to compounds of formula (II): Among the substituents in a compound of formula (II), R 6 is a halogen chosen from F, Cl, Br, and I. The disclosure relates to compositions comprising a compound of formulas (I) or (II) and an excipient. The disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formulas (I) or (II). The disclosure relates to therapeutic uses of compounds of formulas (I) or (II). The disclosure relates to compounds of formula (II), including 5-fluoro-N,N,N-trimethyltryptammonium iodide, 5-fluoro-N,N,N-triethyltryptammonium iodide, 5-fluoro-N,N,N-tri-n-propyltryptammonium iodide, 5-chloro-N,N,N-trimethyltrptammonium iodide, 5-chloro-N,N,N-triethyltryptammonium iodide, 5-bromo-N,N,N-triethyltryptammonium iodide, 5-bromo-N,N,N-tri-n-propyltryptammonium iodide, and 5-bromo-N,N,N-tri-n-propyltryptammonium iodide acetonitrile solvate and their crystalline forms and their compositions and uses.

The disclosure relates to 2-[2.5-diethoxy-4-(ethylsulfanyl)phenyl]ethan-1-aminium chloride (2-(2,5-diethoxy-4-(ethylthio)phenyl)ethane-1-aminium chloride), crystalline 2-(2,5-diethoxy-4-(ethylthio)phenyl) ethane-1-aminium chloride, and specific crystalline forms thereof, including crystalline form 1 of 2-(2,5-diethoxy-4-(ethylthio)phenyl) ethane-1-aminium chloride, to compositions containing the same, and to methods of treatment using them.

Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.

The disclosure relates to a compound of formula (1): The disclosure also relates to a compound of formula (Ia): The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I) or formula (Ia) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) or formula (Ia) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formula (I) or formula (Ia).

The disclosure relates to forms of 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate, including solvates such as methanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (also referred to as 4-glutarato-N,N-diisopropyltryptamine methanol solvate or 4-glutarato-DiPT·MeOH), and crystalline forms thereof such as crystalline form 1 of 4-glutarato-DiPT·MeOH and ethanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (4-glutarato-N,N-diisopropyltryptamine ethanol solvate or 4-glutarato-N,N-DiPT·EtOH), crystalline 4-glutarato-N,N-DiPT·EtOH, and crystalline forms thereof, including crystalline form 1 of 4-glutarato-N,N-DiPT·EtOH; and to pharmaceutical compositions containing them and to methods of treatment using them. The disclosure further relates to crystalline [3-[2-(methylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate (baeocystin), such as crystalline form 1 of baeocystin, and to pharmaceutical compositions containing crystalline baeocystin, such as crystalline form 1 of baeocystin, and to methods of treatment using it.

This disclosure relates to 5-MeO-PiPT chloride, crystalline 5-MeO-PiPT chloride, 4-methylcarbonato-DPT chloride, crystalline 4-methylcarbonato-DPT chloride, NiPT fumarate, crystalline NiPT fumarate, NiPT chloride, crystalline NiPT chloride, MDPT iodide, crystalline MDPT iodide, 5-HT, crystalline 5-HT, 5-HT chloride butanol solvate, crystalline 5-HT chloride butanol solvate, N-cyclohexyltryptammonium fumarate, crystalline N-cyclohexyltryptammonium fumarate, 5-HO-TET iodide, crystalline 5-HO-TET iodide, TALT iodide, crystalline TALT iodide, 4-(4-chlorobenzoato)-DPT chloride, crystalline 4-(4-chlorobenzoato)-DPT chloride, and specific crystalline forms thereof, including crystalline form 1 of 5-MeO-PiPT chloride, crystalline form 1 of 4-methylcarbonato-DPT chloride, crystalline form 1 of NiPT fumarate, crystalline form 1 of NiPT chloride, crystalline form 1 of MDPT iodide, crystalline form 1 of 5-HT, crystalline form 1 of 5-HT chloride butanol solvate, crystalline form 1 of N-cyclohexyltryptammonium fumarate, crystalline form 1 of 5-HO-TET iodide, crystalline form 1 of TALT iodide, and crystalline form 1 of 4-(4-chlorobenzoato)-DPT chloride, to compositions containing the same, and to methods of treatment using them.

The disclosure relates to 2-(5-hydroxy-1H-indol-3-yl)ethan-1-aminium hydrate chloride (5-HT hydrochloride hydrate) and its crystalline form 1, and to pharmaceutical compositions containing 5-HT hydrochloride hydrate or its crystalline form 1 and to methods of treatment using them. The disclosure further relates to crystalline form 1 of (2E)-but-2-enedioic acid bis({2-[4-(acetyloxy)-1H-indol-3-yl]ethyl}(ethyl)propylazanium) (2E)-but-2-enedioate (4-AcO-EPT fumarate fumaric acid), and to pharmaceutical compositions containing crystalline form 1 of 4-AcO-EPT fumarate fumaric acid and to methods of treatment using it. The disclosure further relates to [2-(1H-indol-3-yl)ethyl](methyl)propylazanium iodide (MPT iodide) and its crystalline form 1, and to pharmaceutical compositions containing MPT iodide or its crystalline form 1 and to methods of treatment using them. The disclosure further relates to bis(ethyl[2-(1H-indol-3-yl)ethyl]propylazanium) (2E)-but-2-enedioate (EPT fumarate) and its crystalline form 1, and to pharmaceutical compositions containing EPT fumarate or its crystalline form 1 and to methods of treatment using them. EPT fumarate is a novel compound and crystalline form.

This disclosure relates to crystalline bis(4-hydroxy-N,N-di-n-propyltryptammonium) fumarate tetrahydrate (4-HO-DPT fumarate·4H 2 O) and to crystalline 4-hydroxy-N,N-di-n-propyl-tryptammonium chloride (4-HO-DPT chloride). Compositions containing crystalline 4-HO-DPT fumarate·4H 2 O or crystalline 4-HO-DPT chloride, and methods of use are disclosed.